Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US3596161097
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00DDY1RK9
FULC
Fulcrum Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Fulcrum Therapeutics Inc
ISIN
US3596161097
TICKER
FULC
MIC
XNAS
REUTERS
FULC.OQ
BLOOMBERG
FULC US
Mon, 05.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 5, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 03.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 3, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 03.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 3, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360, i...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 02.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 2, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 01.06.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - June 1, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 01.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 1, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 01.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 1, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 31.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 31, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 30.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 30, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 29.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 29, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 29.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 29, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 26.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 26, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 26.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 25, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 25, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360, i...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 25, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.05.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - May 25, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 24, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 24.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 24, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 24.05.2023       Fulcrum Therapeutics
US3596161097

Did you lose money on investments in Fulcrum Therapeutics, Inc.? If so, please visit Fulcrum Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. New York, New York--(...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 23, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 22.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 22, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 22, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 20.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 20, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 19, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.05.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - May 19, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 18, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 17, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 17, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360, i...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 16, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 15, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc., (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchas...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 15, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 12, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.05.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - May 12, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 11, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 10, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc., (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchas...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 10, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.05.2023       Fulcrum Therapeutics
US3596161097

Did you lose money on investments in Fulcrum Therapeutics, Inc.? If so, please visit Fulcrum Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. New York, New York--(Newsf...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 9, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 8, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360, is...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 8, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 7, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Fulcrum Therapeutics Inc., (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 5, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Fulcrum Therapeutics Inc., (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 5, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 4, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 3, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.05.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - May 2, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.05.2023       Fulcrum Therapeutics
US3596161097

Did you lose money on investments in Fulcrum Therapeutics, Inc.? If so, please visit Fulcrum Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.New York, New York--(Newsfile Corp. - May 2, 2023) - Bernstein Liebhard LLP announces that a securities class act...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 2, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promul...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 30.04.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - April 30, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360,...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.03.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - March 8, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Fulcrum and...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink